- Home
- IVZ vs ARWR Comparison
IVZ vs ARWR Comparison
Compare IVZ & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IVZ | ARWR |
|---|---|---|
| Founded | 1935 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.6B |
| IPO Year | 1995 | 1993 |
Fundamental Metrics
Financial Performance| Metric | IVZ | ARWR |
|---|---|---|
| Price | $26.45 | $67.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $23.56 | ★ $63.70 |
| AVG Volume (30 Days) | ★ 5.1M | 2.4M |
| Earning Date | 01-27-2026 | 02-09-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $6,278,100,000.00 | $829,448,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $17.86 | ★ N/A |
| Revenue Growth | 6.64 | ★ 23258.15 |
| 52 Week Low | $11.60 | $9.57 |
| 52 Week High | $27.48 | $72.36 |
Technical Indicators
Market Signals| Indicator | IVZ | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 60.22 |
| Support Level | $27.05 | $65.94 |
| Resistance Level | $26.96 | $69.71 |
| Average True Range (ATR) | 0.50 | 3.16 |
| MACD | -0.11 | -1.04 |
| Stochastic Oscillator | 31.13 | 56.15 |
Price Performance
Historical ComparisonAbout IVZ Invesco Ltd
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of September 2025, the firm had $2.125 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 47% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.